A Study With CIT-013 in HS Patients

Exclusion Criteria

• •\- Participants for whom an approved therapy with demonstrated clinical benefit is indicated, available and expected to be tolerated, OR choose to proceed with standard of care treatment options over the IP (after being appropriately informed of the treatment options, risks, and benefits).
• •Any current and/or recurrent clinically significant skin condition in the treatment area other than HS,
• •Prior treatment with a recombinant therapeutic protein during the 6 weeks before baseline
• •Prior treatment with any of the following medications before baseline:
• •1. Any other systemic therapy for HS (28 days before baseline)
• •2. Any IV anti-infective therapy (14 days before baseline)
• •History of malignancy with exception of non-melanoma skin cancer that has been excised and cured,